Evidence map›Paper›PMID 37805574›Full record

ArticleHuman genetics2023

How human genetic context can inform pathogenicity classification: FGFR1 variation in idiopathic hypogonadotropic hypogonadism.

Wanxue Xu, Lacey Plummer, Stephanie B Seminara, Ravikumar Balasubramanian, Margaret F Lippincott

Open access · greenAbstract read
In one paragraph

Article in Human genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. A novel mutation in exon 18 ofThe Journal of international medical research · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Wanxue XuReproductive Endocrine Unit of the Department of Medicine, Harvard Reproductive Endocrine Sciences Center, Massachusetts General Hospital, Boston, MA, 02114, USA.
Lacey PlummerReproductive Endocrine Unit of the Department of Medicine, Harvard Reproductive Endocrine Sciences Center, Massachusetts General Hospital, Boston, MA, 02114, USA.
Stephanie B SeminaraReproductive Endocrine Unit of the Department of Medicine, Harvard Reproductive Endocrine Sciences Center, Massachusetts General Hospital, Boston, MA, 02114, USA.
Ravikumar Balasubramanian *Reproductive Endocrine Unit of the Department of Medicine, Harvard Reproductive Endocrine Sciences Center, Massachusetts General Hospital, Boston, MA, 02114, USA.
Margaret F Lippincott *Reproductive Endocrine Unit of the Department of Medicine, Harvard Reproductive Endocrine Sciences Center, Massachusetts General Hospital, Boston, MA, 02114, USA. mlippincott@mgh.harvard.edu.
Reproductive Science Center · USMassachusetts General Hospital · US

Funding

The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
The Genetic Determinants of Human GNRH DeficiencyP50HD028138 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI NEALE, BENJAMIN MICHAEL · 2014 to 2020
$12.9M
The Massachusetts General Hospital Harvard Center for Reproductive MedicineP50HD104224 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI SEMINARA, STEPHANIE BETH · 2021 to 2025
$7.8M
Dissection of the Molecular Basis of Pleiotropy Between GnRH Neuronal Development and Cranial Suture FusionR01DE031452 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI Erica Ellen Davis, Stephanie Beth Seminara · 2022 to 2026
$3.9M
Integrative Approaches to Decipher Genetic Determinants of Disease Penetrance in Prokineticin 2 Pathway Related Human Reproductive DisordersR01HD096324 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI BALASUBRAMANIAN, RAVIKUMAR · 2018 to 2022
$1.7M
Kisspeptin: A Novel Regulator of Insulin in PregnancyK23HD097296 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI LIPPINCOTT, MARGARET FLYNN · 2019 to 2023
$864k
Biologic Roles of Novel Axonal Guidance Genes in Isolated GnRH DeficiencyK23HD077043 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI BALASUBRAMANIAN, RAVIKUMAR · 2014 to 2018
$759k
NCATS NIH HHS UL1 TR002541NICHD NIH HHS K23 HD077043NICHD NIH HHS K23 HD097296NICHD NIH HHS P50 HD028138NICHD NIH HHS P50 HD104224NICHD NIH HHS R01 HD096324NIDCR NIH HHS R01 DE031452
6 · The paper itself

Abstract

Precision medicine requires precise genetic variant interpretation, yet many disease-associated genes have unresolved variants of unknown significance (VUS). We analyzed variants in a well-studied gene, FGFR1, a common cause of Idiopathic Hypogonadotropic Hypogonadism (IHH) and examined whether regional genetic enrichment of missense variants could improve variant classification. FGFR1 rare sequence variants (RSVs) were examined in a large cohort to (i) define regional genetic enrichment, (ii) determine pathogenicity based on the American College of Medical Genetics/Association for Molecular Pathology (ACMG/AMP) variant classification framework, and (iii) characterize the phenotype of FGFR1 variant carriers by variant classification. A total of 143 FGFR1 RSVs were identified in 175 IHH probands (n = 95 missense, n = 48 protein-truncating variants). FGFR1 missense RSVs showed regional enrichment across biologically well-defined domains: D1, D2, D3, and TK domains and linker regions (D2-D3, TM-TK). Using these defined regions of enrichment to augment the ACMG/AMP classification reclassifies 37% (20/54) of FGFR1 missense VUS as pathogenic or likely pathogenic (PLP). Non-proband carriers of FGFR1 missense VUS variants that were reclassified as PLP were more likely to express IHH or IHH-associated phenotypes [anosmia or delayed puberty] than non-proband carriers of FGFR1 missense variants that remained as VUS (76.9% vs 34.7%, p = 0.035). Using the largest cohort of FGFR1 variant carriers, we show that integration of regional genetic enrichment as moderate evidence for pathogenicity improves the classification of VUS and that reclassified variants correlated with phenotypic expressivity. The addition of regional genetic enrichment to the ACMG/AMP guidelines may improve clinical variant interpretation.

Indexed as

HypogonadismGenetic VariationHuman GeneticsHumansPhenotypeReceptor, Fibroblast Growth Factor, Type 1VirulenceFGFR1 protein, humanReceptor, Fibroblast Growth Factor, Type 1

Identifiers

PMID37805574
PMCPMC10977353
OpenAlexW4387424604

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.